Search

Dec 8, 2024
ASH 2024: Beam's CEO John Evans on the company's based editing sickle cell data, and preclinical data on a next generation product meant to broaden the potential patient population
He describes clinical data presented at ASH for BEAM-101 and how he believes it stacks up against competition that is on the market....

Oct 6, 2023
Behind-the-scenes of base editing at Beam Therapeutics
CEO John Evans gives an update on Beam's pipeline and then we take a lab tour to see the science in action with President Pino Ciaramella.

Jan 9, 2023
Beam's Therapeutics' John Evans talks base editing at #JPM23
John Evans talks about base editing as a tool for genetic diseases and cell therapy engineering.